24-[({4-[4-({2-chloro-5-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]phenyl}methyl)phenoxy]butyl}carbamoyl)methyl]-5,5,27,27-tetramethyl-16-oxa-12,20-diazaheptacyclo[15.11.0.0^{3,15}.0^{4,12}.0^{6,11}.0^{20,28}.0^{21,26}]octacosa-1(28),2,4(12),6(11),7,9,21(26),22,24-nonaen-12-ylium-8-sulfonate | 1079083-78-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 24-[({4-[4-({2-chloro-5-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]phenyl}methyl)phenoxy]butyl}carbamoyl)methyl]-5,5,27,27-tetramethyl-16-oxa-12,20-diazaheptacyclo[15.11.0.0^{3,15}.0^{4,12}.0^{6,11}.0^{20,28}.0^{21,26}]octacosa-1(28),2,4(12),6(11),7,9,21(26),22,24-nonaen-12-ylium-8-sulfonate
• 英文别名: 24-[2-[4-[4-[[2-chloro-5-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]phenyl]methyl]phenoxy]butylamino]-2-oxoethyl]-5,5,27,27-tetramethyl-16-oxa-20-aza-12-azoniaheptacyclo[15.11.0.03,15.04,12.06,11.020,28.021,26]octacosa-1(28),2,4(12),6(11),7,9,21(26),22,24-nonaene-8-sulfonate
• CAS: 1079083-78-5
• 化学式: C₅₄H₆₀ClN₃O₁₁S
• 分子量: 994.603
• InChiKey: DJFXSFFMLANJKI-QMHAEFADSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  70
• 可旋转键数：
  12
• 环数：
  10.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  210
• 氢给体数：
  5
• 氢受体数：
  12

反应信息

• 作为产物：
  描述：

  Cy3B NHS ester 、 (2S,3R,4R,5S,6R)-2-(3-(4-(4-aminobutoxy)benzyl)-4-chlorophenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 在 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 24-[({4-[4-({2-chloro-5-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]phenyl}methyl)phenoxy]butyl}carbamoyl)methyl]-5,5,27,27-tetramethyl-16-oxa-12,20-diazaheptacyclo[15.11.0.0^{3,15}.0^{4,12}.0^{6,11}.0^{20,28}.0^{21,26}]octacosa-1(28),2,4(12),6(11),7,9,21(26),22,24-nonaen-12-ylium-8-sulfonate
  参考文献：
  名称：

  Design and synthesis of fluorescent SGLT2 inhibitors

  摘要：

  The design and synthesis of the first fluorophore-conjugated SGLT2 inhibitors is described. The mode of linking the fluorophore to the SGLT2 pharmacophore was found to be crucial in achieving optimum potency. Superior potency to phlorizin was provided by examples containing TAMRA, BODIPY, Cy3B and NBD fluorophores. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.08.036

文献信息

• Design and synthesis of fluorescent SGLT2 inhibitors
  作者：Mark I. Lansdell、Denise J. Burring、David Hepworth、Matthew Strawbridge、Emily Graham、Thierry Guyot、Mark S. Betson、James D. Hart

  DOI：10.1016/j.bmcl.2008.08.036

  日期：2008.9

  The design and synthesis of the first fluorophore-conjugated SGLT2 inhibitors is described. The mode of linking the fluorophore to the SGLT2 pharmacophore was found to be crucial in achieving optimum potency. Superior potency to phlorizin was provided by examples containing TAMRA, BODIPY, Cy3B and NBD fluorophores. (C) 2008 Elsevier Ltd. All rights reserved.